AbbVie showed solid financial performance in Q1 2026 with double-digit revenue growth and a healthy rise in adjusted earnings per share. While acquisition talks may temporarily weigh on earnings, they could boost revenues in the long run. The stock's improved market multiples and attractive dividend yield suggest it remains a good long-term investment. Investors should watch how acquisition developments unfold as they could impact near-term earnings but potentially enhance future growth.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
